The Science Behind XEOMIN®

State-of-the-art Proprietary Manufacturing

Clostridium botulinum is a naturally occurring toxin. Manufacturers use a selected strain, bred biologically in optimal conditions, to produce therapeutic botulinum toxin products.1 Botulinum toxin type A has a combined (neurotoxin + accessory proteins) molecular weight of 900 kDa, of which 150 kDa is the neurotoxin.2

XEOMIN is made from a purified botulinum toxin type A that is produced from fermentation of Hall strain Clostridium botulinum serotype A.1 The molecular weight of XEOMIN is 150 kDa because the proprietary manufacturing process of XEOMIN isolates the active toxin from accessory proteins and reduces the proteins. As a result, XEOMIN is formulated to have high biological activity with a low protein load.3

Purifying Botulinum Toxin Type A Into XEOMIN

The active neurotoxin is separated from accessory proteins

The clinical significance of the absence or presence of accessory proteins, including any impact on safety or efficacy, has not been established. This information about the XEOMIN manufacturing process and the properties of incobotulinumtoxinA is not intended to imply superiority over other botulinum toxin A products.

Discover More Information on the Manufacturing of XEOMIN

Watch the video

The potency units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products.

XEOMIN Mechanism of Action

XEOMIN blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve endings. This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of SNAP25, a presynaptic target protein essential for the release of acetylcholine. In both muscles and glands, impulse transmission is re-established by the formation of new nerve endings.1

Watch the Video

References

  1. XEOMIN® [package insert]. Raleigh, NC: Merz North America, Inc; 2018.
  2. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-1768.
  3. Dressler D. Botulinum toxin drugs: future developments. J Neural Transm. 2008;115(4):575-577.